According to filings with the U.S. Securities and Exchange Commission, SpectraWAVE is raising up to $50,287,674.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Eman Namati played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SpectraWAVE
SpectraWAVE, located in Bedford, Mass., is a privately held medical device company founded in 2017 to provide unrivaled optical and computational insights to improve the treatment and outcomes for patients with coronary artery disease (CAD). CAD, the buildup of plaque in the wall of the arteries that supply blood to the heart, affects 18.2 million adults age 20 and older. In CAD patients that undergo percutaneous stent placement, it is estimated that one in five patients experience adverse events within two years. SpectraWAVEs state of the art HyperVue Imaging System combines next generation DeepOCT images and near infrared spectroscopy (NIRS) with workflows optimized for the cardiac catheterization lab. The HyperVue Imaging System is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The NIRS capability of the system is intended for the identification of patients and plaques at increased risk of major adverse cardiac events.

To learn more about SpectraWAVE, visit http://www.spectrawave.com/
SpectraWAVE Linkedin Page: https://www.linkedin.com/company/spectrawave-inc/

Contact:
Eman Namati, Chief Executive Officer
781-701-8148
https://www.linkedin.com/in/eman-namati/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.